Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP066
MIFTS: 61

Hyperglycemia

Categories: Blood diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hyperglycemia

About this section

MalaCards integrated aliases for Hyperglycemia:

Name: Hyperglycemia 12 74 29 54 6 42 43 15 71

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:4195
MeSH 43 D006943
NCIt 49 C26797
SNOMED-CT 67 80394007
ICD10 32 R73.9
UMLS 71 C0020456
Sources

Summaries for Hyperglycemia

About this section
MedlinePlus : 42 Hyperglycemia means high blood sugar or glucose. Glucose comes from the foods you eat. Insulin is a hormone that moves glucose into your cells to give them energy. Hyperglycemia happens when your body doesn't make enough insulin or can't use it the right way. People with diabetes can get hyperglycemia from not eating the right foods or not taking medicines correctly. Other problems that can raise blood sugar include infections, certain medicines, hormone imbalances, or severe illnesses.

MalaCards based summary : Hyperglycemia is related to diabetes mellitus, permanent neonatal 4 and diabetes mellitus, permanent neonatal 1, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hyperglycemia is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Developmental Biology and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Lixisenatide and Granisetron have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and brain, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 74 Hyperglycemia is a condition in which an excessive amount of glucose circulates in the blood plasma.... more...

Sources

Related Diseases for Hyperglycemia

About this section

Diseases related to Hyperglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 880)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, permanent neonatal 4 33.6 PDX1 KCNJ11 INS GCK ABCC8
2 diabetes mellitus, permanent neonatal 1 33.4 PDX1 KCNJ11 INS GCK ABCC8
3 transient neonatal diabetes mellitus 33.4 PDX1 KCNJ11 INS GCK ABCC8
4 maturity-onset diabetes of the young, type 2 33.4 PDX1 KCNJ11 INS HNF1A GCK GCG
5 diabetes mellitus, ketosis-prone 33.2 SLC5A2 KCNJ11 INS GCG DPP4 ALB
6 donohue syndrome 33.0 IRS1 INSR INS IGF1 GCK
7 hyperinsulinism 32.7 SST PPARG LEP KCNJ11 IRS1 INSR
8 diabetes mellitus, insulin-dependent, 20 32.7 INS IGF1 HNF1A
9 pancreatic cholera 32.5 SST GCG
10 diabetes mellitus, type i 32.4 SST SLC5A2 PPARG PDX1 LEP INSR
11 hypoglycemia 32.2 SST KCNJ11 INSR INS IGF1 IAPP
12 diabetes mellitus, noninsulin-dependent 32.1 SST SLC5A2 PPARG PDX1 LEP KCNJ11
13 microvascular complications of diabetes 5 31.9 INS IGF1 ALB AKR1B1
14 lipid metabolism disorder 31.8 PPARG LEP IRS1 INSR INS ADIPOQ
15 fatty liver disease, nonalcoholic 1 31.6 LEP INS ADIPOQ
16 atherosclerosis susceptibility 31.5 PPARG LEP INS ALB ADIPOQ
17 vascular disease 31.5 PPARG LEP INS IGF1 ALB ADIPOQ
18 diabetic neuropathy 31.4 LEP INS AKR1B1
19 gestational diabetes 31.4 PPARG LEP KCNJ11 IRS1 INSR INS
20 pancreatitis 31.4 SST PDX1 INS GCG ALB
21 myocardial infarction 31.3 PPARG LEP INS IGF1 DPP4 ALB
22 glucose intolerance 31.3 PPARG LEP KCNJ11 IRS1 INSR INS
23 retinal vascular disease 31.3 INS IGF1 ALB AKR1B1
24 autonomic neuropathy 31.2 INS GCG ALB AKR1B1
25 kidney disease 31.2 PPARG LEP INS GCG DPP4 ALB
26 acute insulin response 31.2 KCNJ11 INS GCG ABCC8
27 peripheral nervous system disease 31.2 LEP INS IGF1 GCG DPP4 ALB
28 microvascular complications of diabetes 1 31.2 SST INS IGF1 AKR1B1
29 microvascular complications of diabetes 3 31.2 MALAT1 INS ALB AKR1B1
30 acute cystitis 31.2 SLC5A2 INS DPP4 ALB
31 insulinoma 31.2 SST PDX1 INS IAPP HNF1A GCK
32 acromegaly 31.1 SST LEP INS IGF1 ADIPOQ
33 insulin-like growth factor i 31.1 LEP IRS1 INSR INS IGF1
34 diabetic encephalopathy 31.1 IRS1 INS IGF1
35 macular retinal edema 31.1 INS ALB AKR1B1
36 liver disease 31.1 LEP IRS1 INSR INS ALB ADIPOQ
37 arteries, anomalies of 31.0 PPARG LEP INS ALB ADIPOQ
38 hyperuricemia 31.0 PPARG LEP INS ALB
39 non-alcoholic fatty liver disease 31.0 PPARG LEP IRS1 INSR INS GCG
40 heart disease 31.0 PPARG LEP INS IGF1 GCG ALB
41 chronic kidney disease 31.0 SLC5A2 LEP INS IGF1 ALB ADIPOQ
42 polycystic ovary syndrome 30.9 PPARG LEP IRS1 INSR INS IGF1
43 neonatal diabetes mellitus 30.9 PDX1 KCNJ11 INS HNF1A GCK GCG
44 monogenic diabetes 30.9 PDX1 KCNJ11 INS HNF1A GCK ABCC8
45 bone resorption disease 30.9 PPARG LEP INS IGF1 ALB
46 maturity-onset diabetes of the young 30.9 SST PPARG PDX1 LEP KCNJ11 IRS1
47 hyperandrogenism 30.9 PPARG INSR INS IGF1 ADIPOQ
48 hypothyroidism 30.8 SST LEP INS IGF1 ALB ADIPOQ
49 sleep apnea 30.8 PPARG LEP INS IGF1 ALB ADIPOQ
50 sexual disorder 30.8 INS IGF1 ALB

Graphical network of the top 20 diseases related to Hyperglycemia:



Diseases related to Hyperglycemia
Sources

Symptoms & Phenotypes for Hyperglycemia

About this section

UMLS symptoms related to Hyperglycemia:


seizures, fever, dyspnea, edema, cachexia, vertigo, headache, syncope, cyanosis, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, symptoms

MGI Mouse Phenotypes related to Hyperglycemia:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCK
2 growth/size/body region MP:0005378 10.36 ADIPOQ AKR1B1 DPP4 GCK HNF1A IAPP
3 endocrine/exocrine gland MP:0005379 10.32 ABCC8 ADIPOQ ALB DPP4 GCK HNF1A
4 cardiovascular system MP:0005385 10.26 ADIPOQ ALB DPP4 GCK IGF1 INS
5 cellular MP:0005384 10.25 ADIPOQ ALB GCK HNF1A IGF1 INS
6 adipose tissue MP:0005375 10.24 ADIPOQ HNF1A IGF1 INS INSR IRS1
7 immune system MP:0005387 10.22 ADIPOQ ALB DPP4 IAPP IGF1 INS
8 mortality/aging MP:0010768 10.2 ADIPOQ AKR1B1 ALB DPP4 GCK HNF1A
9 digestive/alimentary MP:0005381 10.1 ALB HNF1A INS INSR LEP PDX1
10 liver/biliary system MP:0005370 10.07 ADIPOQ ALB GCK HNF1A INS INSR
11 muscle MP:0005369 10 ADIPOQ ALB HNF1A IGF1 INS INSR
12 renal/urinary system MP:0005367 9.73 ADIPOQ AKR1B1 ALB GCK HNF1A IGF1
13 no phenotypic analysis MP:0003012 9.7 ABCC8 HNF1A INS KCNJ11 PDX1 PPARG
14 skeleton MP:0005390 9.4 ADIPOQ AKR1B1 HNF1A IAPP IGF1 INS
Sources

Drugs & Therapeutics for Hyperglycemia

About this section

Drugs for Hyperglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 693)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lixisenatide Approved Phase 4 320367-13-3
2
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
3
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
4
parecoxib Approved Phase 4 198470-84-7
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
6
Rilpivirine Approved Phase 4 500287-72-9
7
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
8
Cobicistat Approved Phase 4 1004316-88-4
9
Glucagon Approved Phase 4 16941-32-5
10
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
11
Insulin glulisine Approved Phase 4 207748-29-6
12
Gliclazide Approved Phase 4 21187-98-4 3475
13
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
14
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
15
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
16
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
17
Linagliptin Approved Phase 4 668270-12-0 10096344
18
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
19
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
20
Ziprasidone Approved Phase 4 146939-27-7 60854
21
Simvastatin Approved Phase 4 79902-63-9 54454
22
Glimepiride Approved Phase 4 93479-97-1 3476
23
Pramlintide Approved, Investigational Phase 4 151126-32-8
24
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
25
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
26
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
27
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
28
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
29
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
30
Febuxostat Approved Phase 4 144060-53-7 134018
31
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
32
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
33
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
34
Glycerol Approved, Investigational Phase 4 56-81-5 753
35
Atenolol Approved Phase 4 29122-68-7 2249
36
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
37
Enalaprilat Approved Phase 4 76420-72-9 6917719
38
Clozapine Approved Phase 4 5786-21-0 2818
39
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
40
Cetirizine Approved Phase 4 83881-51-0 2678
41
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
42
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
43
Mycophenolic acid Approved Phase 4 24280-93-1 446541
44
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
45
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
46
Haloperidol Approved Phase 4 52-86-8 3559
47
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
48
Cefpirome Approved Phase 4 84957-29-9 5479539
49
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
50
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570

Interventional clinical trials:

(show top 50) (show all 1784)
# Name Status NCT ID Phase Drugs
1 Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes: The FIT Study Unknown status NCT03057470 Phase 4 50% bolus insulin correction;100% bolus insulin correction;150% bolus insulin correction
2 ß-Cell Function and Glycemic Control of Basal Insulin, Metformin or Sitagliptin in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia Unknown status NCT01717911 Phase 4 Insulin;Metformin;Sitagliptin
3 A Pilot Study of Outpatient Discharge Therapy With Saxagliptin + Metformin XR or Sulphonylurea for Recently Diagnosed Type 2 Diabetes Presenting With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
4 Basal-bolus Insulin Therapy With Insulin Degludec and Insulin Aspart Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study Unknown status NCT03244241 Phase 4 Insulin Degludec 100 UNT/ML [Tresiba]
5 The Therapeutic Effects of Combination of Insulin With Berberine on the Patients With Stess Hyperlipemia:a Prospective, Double Blind, Randomized, Placebo-controlled, Single-center Clinical Trial Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
6 Randomized Controlled Clinical Study of Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
7 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
8 A Prospective, Multi-center, Randomized, Controlled Study to Evaluate the Effect of DiPeptidyl-Peptidase 4 Inhibitor on Vascular Healing After Biodegradable Polymer Based Sirolimus Eluting Stent Implantation in Diabetic Patients: OCT Study (DIAMOND-OCT) Unknown status NCT02802644 Phase 4 Sitagliptin;Non DPP-4 Inhibitor
9 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
10 Multiple Substitution of First Phase Insulin Response With a Rapid Action Insuli Analogue in Patient With Newly Diagnosed Type 2 Diabtes. Unknown status NCT00254085 Phase 4 Insulin Aspart
11 An Open-label, Randomized, Active-controlled Study to Compare the Effect of DPP-IV Inhibitor and TZD as add-on Therapy to Metformin on Glycemic Variability and Oxidative Stress in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy Unknown status NCT01339143 Phase 4 Galvus (vildagliptin);pioglitazone
12 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
13 The Effects of Short-Term Exenatide Therapy on the Beta-Cell Function and Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients Unknown status NCT01270191 Phase 4 Exenatide;Humulin-N
14 Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) Unknown status NCT02577159 Phase 4 Dapagliflozin
15 A Randomized Controlled Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU Unknown status NCT02491346 Phase 4
16 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
17 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
18 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
19 To Compare the Efficacy and Safety Between Pioglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin and Placebo Control Group in Patients With Type 2 Diabetes Unknown status NCT00991055 Phase 4 Pioglitazone
20 Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
21 Effect of Bydureon on Carotid Atherosclerosis Progression in T2DM Unknown status NCT02162550 Phase 4 Bydureon;placebo
22 Randomised Clinical Trial to Evaluate the Obtention of Blood Samples Through an Arterial Catheter to Monitor Glycose Levels Unknown status NCT01176279 Phase 4
23 The Efficacy and Safety of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase 4 Inhibitor Added to Premix Insulin Injection Twice Daily in Uncontrolled Type 2 Diabetes Patients Unknown status NCT03458715 Phase 4 SGLT2 inhibitor (Empagliflozin 25 MG);DPP4 inhibitor (Linagliptin 5 MG)
24 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance, Tramadol PCA and Early Postoperative Enteral Nutrition in Patients After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
25 The Effect of Insulin Infusion on Metabolic Control and Inflammation in Diabetic Patients During Cardio-vascular Intervention and/or Treatment for Acute Foot Ulcer Infection. Unknown status NCT00700154 Phase 4
26 Treatment by Subcutaneous Continuous Infusion of Insulin by Portable Pump Versus Discontinuous Infusion of Insulin by Multi-injections in the Type 2 Diabetes: Study of the Insulinosensibility in the 2 Types of Treatments Unknown status NCT01889914 Phase 4 2 different procedures of administration of insulin
27 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
28 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
29 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Unknown status NCT02501850 Phase 4 Liraglutide;metformin
30 Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy Unknown status NCT03112538 Phase 4 Multiple daily injections of insulin
31 A Randomized Evaluation of the Effects of Valsartan and Aliskiren in Combination Versus Tekturna Alone on Hemostatic Biomarkers in Patients With Newly Diagnosed Mild to Moderate Hypertension and Type 2 Diabetes Mellitus Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
32 Type 2 Diabetes Mellitus: Role of Inflammation and Innate Immunity in The Pathogenesis of Endothelial Dysfunction and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
33 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
34 A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT) Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
35 Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1) Unknown status NCT02798068 Phase 4 Solu-medrol or placebo administration
36 Prospective Evaluation of Perioperative Steroid Dosing on Postsurgical Edema in Orthognathic Surgery Unknown status NCT03190642 Phase 4 Methylprednisolone
37 Randomized, Open Prospective Study of the Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
38 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
39 Absorption and Utilization of a Mixed Meal in Type 1 Diabetes: Creation of a Biological and In Silico Biobank for the Optimization of Artificial Pancreas Systems. A Pilot Study. Unknown status NCT01800734 Phase 4
40 Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients Unknown status NCT03091881 Phase 4 Granisetron 0.1 MG/ML;Placebos
41 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
42 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
43 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia Completed NCT01184014 Phase 4 NPH insulin plus Complete Insulin Orders;Complete Insulin Orders
44 Hyperglycemia and Effects of Daily 100 Milligrams Versus 200 Milligrams of Hydrocortisone Therapy in Patients With Septic Shock: A Double-Blind Randomized Controlled Trial Completed NCT02266264 Phase 4 Hydrocortisone
45 Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation Completed NCT00779701 Phase 4 Insulin
46 The Effect of Postprandial Hyperglycemia on the Arterial Stiffness in Patients With Type 2 Diabetes Completed NCT01159938 Phase 4 Lispro
47 Post Marketing Clinical Study of Aripiprazole in Patients With Schizophrenia - Effects on Glucose Metabolism- Completed NCT00392197 Phase 4 Aripiprazole
48 Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia Completed NCT00362778 Phase 4 Insulin
49 The Effect of Insulin Glargine on Glycemic Control, Morbidity, and Length of Stay in Hospitalized Subjects With Diabetes Receiving Enteral Nutrition Completed NCT00177398 Phase 4 Glargine insulin vs regular insulin
50 Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy Completed NCT02155374 Phase 4 Sliding scale insulin;Intermediate acting insulin;Glucose lowering medication;Chemotherapy

Search NIH Clinical Center for Hyperglycemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Insulin
insulin beef, isophane
insulin beef-pork, isophane
insulin degludec
Insulin Glargine
insulin human, isophane
Insulin Lispro
insulin pork, isophane
Insulin, Aspart Protamine, Human
Insulin, Aspart, Human
Insulin, Glulisine, Human
Insulin, Prompt Zinc, Beef
Insulin, Prompt Zinc, Beef-Pork
Insulin, Prompt Zinc, Pork
Insulin, Protamine Lispro, Human
insulin, protamine zinc, beef
Insulin, Protamine Zinc, Beef-Pork
Insulin, Protamine Zinc, Pork
Insulin, Regular, Beef
insulin, regular, beef-pork
Insulin, Regular, Pork
Insulin, Zinc, Human
Insulin, Zinc, Pork
INSULIN,DETEMIR,HUMAN
INSULIN,REGULAR,HUMAN BUFFERED
Lente Insulin, Beef
Lente Insulin, Beef-Pork
Regular Insulin, Human
Ultralente Insulin, Beef
Ultralente Insulin, Beef-Pork
Ultralente Insulin, Human

Cochrane evidence based reviews: hyperglycemia

Sources

Genetic Tests for Hyperglycemia

About this section

Genetic tests related to Hyperglycemia:

# Genetic test Affiliating Genes
1 Hyperglycemia 29
Sources

Anatomical Context for Hyperglycemia

About this section

MalaCards organs/tissues related to Hyperglycemia:

40
Endothelial, Liver, Brain, Kidney, Heart, Pancreas, Testes
Sources

Publications for Hyperglycemia

About this section

Articles related to Hyperglycemia:

(show top 50) (show all 30435)
# Title Authors PMID Year
1
Associations of maternal hyperglycemia in the second and third trimesters of pregnancy with prematurity. 42 61
32332610 2020
2
Acarbose versus Repaglinide in Diabetes Treatment: A New Appraisal of Two Old Rivals. 42
32200914 2020
3
Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. 42
32345662 2020
4
Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. 61 54
20184965 2010
5
Insulin-like growth factor-I-stimulated insulin receptor substrate-1 negatively regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells. 54 61
20207740 2010
6
Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. 61 54
20207828 2010
7
C-reactive protein -717C>T genetic polymorphism associates with esophagectomy-induced stress hyperglycemia. 54 61
20145925 2010
8
Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. 54 61
20197503 2010
9
[Endothelial dysfunction in diabetes]. 61 54
20446576 2010
10
The effect of insulin signaling on female reproductive function independent of adiposity and hyperglycemia. 54 61
20176725 2010
11
Hyperglycemia and hypoxia are interrelated in their teratogenic mechanism: studies on cultured rat embryos. 54 61
20127827 2010
12
Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors. 54 61
20425568 2010
13
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. 54 61
20222801 2010
14
Lifestyle, anthropometric, and obesity-related physiologic determinants of insulin-like growth factor-1 in the Third National Health and Nutrition Examination Survey (1988-1994). 61 54
20159489 2010
15
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. 54 61
20299674 2010
16
Bone marrow transplantation temporarily improves pancreatic function in streptozotocin-induced diabetes: potential involvement of very small embryonic-like cells. 61 54
20110858 2010
17
Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. 61 54
19968982 2010
18
Addressing hyperglycemia from hospital admission to discharge. 54 61
20078323 2010
19
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. 61 54
20448799 2010
20
Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients. 61 54
19783893 2010
21
Hyperglycemia adversely modulates endothelial nitric oxide synthase during anesthetic preconditioning through tetrahydrobiopterin- and heat shock protein 90-mediated mechanisms. 61 54
20124983 2010
22
Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes. 54 61
19923796 2010
23
Acute hyperglycemia produces transient improvement in glucose transporter type 1 deficiency. 54 61
20186957 2010
24
Heterocyclic indazole derivatives as SGK1 inhibitors, WO2008138448. 54 61
20021289 2010
25
Pdx1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce hyperglycemia in diabetic mice. 61 54
19757377 2010
26
Naturally occurring glucokinase mutations are associated with defects in posttranslational S-nitrosylation. 54 61
19934346 2010
27
Protective effects of grape seed proanthocyanidin extracts on cerebral cortex of streptozotocin-induced diabetic rats through modulating AGEs/RAGE/NF-kappaB pathway. 61 54
20495289 2010
28
Increased circulating IL-8 is associated with reduced IGF-1 and related to poor metabolic control in adolescents with type 1 diabetes mellitus. 54 61
19773182 2009
29
Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. 61 54
19720878 2009
30
Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. 54 61
19945407 2009
31
"Blinding" of AMP-dependent kinase by methylglyoxal: a mechanism that allows perpetuation of hepatic insulin resistance? 54 61
19643547 2009
32
[Coactivators in energy metabolism: peroxisome proliferator-activated receptor-gamma coactivator 1 family]. 61 54
20078951 2009
33
Contribution of glucose tolerance and gender to cardiac adiposity. 61 54
19820028 2009
34
Low plasma adiponectin level, white blood cell count and Helicobacter pylori titre independently predict abnormal pancreatic beta-cell function. 61 54
19747747 2009
35
Targeting SGK1 in diabetes. 54 61
19764891 2009
36
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. 61 54
19790256 2009
37
High glucose-induced oxidative stress alters estrogen effects on ERalpha and ERbeta in human endothelial cells: reversal by AMPK activator. 54 61
19635557 2009
38
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. 61 54
19758106 2009
39
Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis. 54 61
19878567 2009
40
Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. 54 61
19564454 2009
41
Foxo1 links hyperglycemia to LDL oxidation and endothelial nitric oxide synthase dysfunction in vascular endothelial cells. 61 54
19584310 2009
42
Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation. 54 61
19647774 2009
43
Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. 54 61
19624560 2009
44
Mild fasting hyperglycemia in children: high rate of glucokinase mutations and some risk of developing type 1 diabetes mellitus. 61 54
19309449 2009
45
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts. 54 61
19477910 2009
46
Hyperinsulinemia predicts survival in a hyperglycemic mouse model of critical illness. 54 61
19623043 2009
47
Identification of a novel beta-cell glucokinase (GCK) promoter mutation (-71G>C) that modulates GCK gene expression through loss of allele-specific Sp1 binding causing mild fasting hyperglycemia in humans. 54 61
19411616 2009
48
PDX1 deficiency causes mitochondrial dysfunction and defective insulin secretion through TFAM suppression. 54 61
19656489 2009
49
Intestinal cholecystokinin controls glucose production through a neuronal network. 54 61
19656488 2009
50
Exposure of human keratinocytes to ischemia, hyperglycemia and their combination induces oxidative stress via the enzymes inducible nitric oxide synthase and xanthine oxidase. 54 61
19539448 2009
Sources

Variations for Hyperglycemia

About this section

ClinVar genetic disease variations for Hyperglycemia:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KLF11 NM_003597.5(KLF11):c.23G>A (p.Gly8Asp)SNV Uncertain significance 523462 rs1553312826 2:10183866-10183866 2:10043739-10043739

Copy number variations for Hyperglycemia from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 44162 10 52900000 70600000 Copy number TFAM Hyperglycemia
Sources

Expression for Hyperglycemia

About this section
Search GEO for disease gene expression data for Hyperglycemia.
Sources

Pathways for Hyperglycemia

About this section

Pathways related to Hyperglycemia according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Developmental Biology 65
Show member pathways
 13.44 PPARG PDX1 LEP IRS1 INS IAPP
2
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 65
Show member pathways
 13.23 PPARG LEP IRS1 INSR INS GCG
3
Aldosterone synthesis and secretion 36
Show member pathways
 12.85 PDX1 KCNJ11 INS GCK GCG ALB
4
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.72 LEP IRS1 INSR INS ADIPOQ
5
Prolactin Signaling Pathway 36 1
Show member pathways
 12.4 LEP IRS1 INS GCK
6
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.37 PPARG LEP IRS1 INSR INS IGF1
7
Integration of energy metabolism 65
Show member pathways
 12.32 KCNJ11 INS GCG ADIPOQ ABCC8
8
Glucose / Energy Metabolism 4
12.3 SLC5A2 PPARG PDX1 IRS1 INSR INS
9
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.26 PPARG IRS1 INSR IGF1
10
Peptide hormone metabolism 65
Show member pathways
 12.21 LEP INS IGF1 GCG DPP4
11
AMPK Enzyme Complex Pathway 63
Show member pathways
 12.15 LEP IRS1 INSR INS
12
Longevity regulating pathway 36
Show member pathways
 12.06 PPARG IRS1 INSR INS IGF1 ADIPOQ
13
FoxO signaling pathway 36
Show member pathways
 12.03 IRS1 INSR INS IGF1
14
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 64
12.01 PDX1 INS IGF1 ALB
15
Hepatic ABC Transporters 63
Show member pathways
 11.99 PDX1 INSR INS HNF1A GCK
16
Adipogenesis 1
11.92 PPARG LEP IRS1 INS IGF1 HNF1A
17
Regulation of beta-cell development 65
Show member pathways
 11.85 PDX1 INS IAPP HNF1A GCK
18
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.81 PPARG LEP INS IGF1 ADIPOQ
19
Adipocytokine signaling pathway 36
11.66 LEP IRS1 ADIPOQ
20
AGE/RAGE pathway 1
11.63 IRS1 INSR INS
21
Regulation of lipolysis in adipocytes 36
11.55 IRS1 INSR INS
22
Incretin synthesis, secretion, and inactivation 65
Show member pathways
 11.54 LEP GCG DPP4
23
Development_Leptin signaling via PI3K-dependent pathway 22
11.54 LEP KCNJ11 IRS1 ABCC8
24
Signaling events mediated by PTP1B 1
11.51 LEP IRS1 INSR INS
25
Ovarian steroidogenesis 36
11.49 INSR INS IGF1
26
Insulin Pathway 1
11.41 IRS1 INSR INS
27
Aldosterone-regulated sodium reabsorption 36
11.35